Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) announced that recently, Fosun Carey (Shanghai) Biotechnology Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), initiated phase II clinical trials on FKC516 injection (hereinafter referred to as “FKC516”) for recurrent or refractory B-cell non-Hodgkin lymphoma (r/RB-NHL) in China.

Zhitongcaijing · 1d ago
Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) announced that recently, Fosun Carey (Shanghai) Biotechnology Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), initiated phase II clinical trials on FKC516 injection (hereinafter referred to as “FKC516”) for recurrent or refractory B-cell non-Hodgkin lymphoma (r/RB-NHL) in China.